
Patients with zzso in particular those requiring systemic treatment, tend to be above normal zzso zzso is associated with psoriasis and contributes significantly to the increased cardiovascular risk in these zzso Most zzso used to treat psoriasis in the European Union are fixed zzso zzso zzso zzso and zzso Apart from zzso dosing regimens do not account for weight, with the exception of zzso the dose of which should be doubled in patients weighing more than 100 zzso The aim of this study was to review the available evidence on the association of obesity and zzso and the effect of body weight or obesity on the efficacy of zzso as well as their practical implications in daily zzso A review was performed of the literature relating to obesity and psoriasis and weight effect, including zzso zzso on the efficacy of the zzso available for treatment of psoriasis in the European Union, namely zzso zzso zzso and zzso zzso responses with fixed dose biological agents are less frequent in patients with increasing weight, especially above 100 zzso who account for approximately zzso to zzso of patients in clinical zzso Body weight effect on drug clearance might partly account for this zzso The data are limited to zzso zzso often with no statistical significance zzso Further studies, including zzso zzso of clinical trials and zzso evaluations, are required to assess the issue of body weight and response to therapy of the zzso zzso response appears to be independent of body mass zzso zzso zzso dose adjustments and the impact of treatment on body weight changes also require additional zzso 

